Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of TG Therapeutics (NASDAQ:TGTX), a clinical-stage biopharmaceutical company focused on developing therapies to treat cancer, temporarily plunged as much as 15% this morning after reporting preliminary clinical results of a phase 2 study in combination with Pharmacyclics' (NASDAQ:PCYC) Imbruvica (formerly ibrutinib). Shares have since rebounded and are now higher by 3% on the day as of this writing.
So what: According to TG Therapeutics' press release, TG-1101 in combination with Imbruvica led to an impressive 90% overall response rate (out of 10 evaluable patients) at the first efficacy assessment in patients with previously treated chronic lymphocytic leukemia and mantle cell lymphoma. As noted in its press release, "The addition of TG-1101 appears to abrogate ibrutinib related lymphocytosis in patients with CLL, with patients experiencing a median ~80% reduction in their absolute lymphocyte count (ALC) by month 4 following initiation of combination therapy." In addition, the combo appeared to be generally safe and well-tolerated in the initial 28 patients, though one grade 3/4 adverse event was reported that led to study discontinuation.
Now what: Today's sharp, but temporary move lower merely looks like a combination of emotional trading and profit taking following TG Therapeutics' 92% surge higher over the past month. Although the data, while preliminary, would certainly appear to indicate that Imbruvica could have legs as a combination therapy, and that a combination with TG-1101 might be one of those therapies that eventually reaches the market. Admittedly, with just 10 evaluable patients I'm not reading to declare this a wholly effective combo just yet, but I believe the case has been made that this combo should be followed closely going forward.
One final thing to consider, however, is that as a purely clinical-stage company TG Therapeutics may choose to offer shares for sale in order to raise cash for future research studies – a somewhat common practice in the biotech sector. Investors may want to consider the potential for dilution following TG's large run higher.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.